Triple-Negative Breast Cancer Latest Advances

Find the Latest Research About Triple-Negative Breast Cancer

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4026 publications

A Case in Which Locoregional Surgery and S-1 Were Effective for Locally Advanced Stage Ⅳ Triple Negative Breast Cancer Who Refused Chemotherapy Accompanied by Hair Loss

A Case in Which Locoregional Surgery and S-1 Were Effective for Locally Advanced Stage Ⅳ Triple Negative Breast Cancer Who Refused Chemotherapy Accompanied by Hair Loss

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 17, 2026

Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer.

Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer.

Journal: Journal of medicinal chemistry
Published: January 13, 2026

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.

Journal: BMJ (Clinical research ed.)
Published: January 12, 2026

In-silico Exploration of the Possible Prolactin Pathway Related Targets of B. Monnieri against Triple Negative Breast Cancer: Selection of the Best Target Ligand Combination.

In-silico Exploration of the Possible Prolactin Pathway Related Targets of B. Monnieri against Triple Negative Breast Cancer: Selection of the Best Target Ligand Combination.

Journal: Cell biochemistry and biophysics
Published: January 05, 2026

Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review.

Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review.

Journal: European journal of breast health
Published: December 25, 2025

Adjuvant carboplatin for high risk triple negative breast cancer.

Adjuvant carboplatin for high risk triple negative breast cancer.

Journal: BMJ (Clinical research ed.)
Published: December 23, 2025

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.

Journal: BMJ (Clinical research ed.)
Published: December 23, 2025

Corrigendum to "CXCL8 is a prognostic biomarker and correlated with TNBC brain metastasis and immune infiltration" [Int. Immunopharmacol. 103 (2022) 108454].

Corrigendum to "CXCL8 is a prognostic biomarker and correlated with TNBC brain metastasis and immune infiltration" [Int. Immunopharmacol. 103 (2022) 108454].

Journal: International immunopharmacology
Published: December 20, 2025

ASO Author Reflections: Treating Secondary Triple Negative Breast Cancer in Younger Women.

ASO Author Reflections: Treating Secondary Triple Negative Breast Cancer in Younger Women.

Journal: Annals of surgical oncology
Published: December 17, 2025

Transformation of nanoparticles into hydrogels for long-acting and sensitized apoptosis therapy of triple negative breast cancer.

Transformation of nanoparticles into hydrogels for long-acting and sensitized apoptosis therapy of triple negative breast cancer.

Journal: Biomaterials science
Published: December 16, 2025

Correction: Amino acid transporter LAT1 (SLC7A5) promotes metabolic rewiring in TNBC progression through the L-Trp/QPRT/NAD+ pathway.

Correction: Amino acid transporter LAT1 (SLC7A5) promotes metabolic rewiring in TNBC progression through the L-Trp/QPRT/NAD+ pathway.

Journal: Journal of experimental & clinical cancer research : CR
Published: December 12, 2025

Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer.

Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer.

Journal: Journal of experimental & clinical cancer research : CR
Published: December 05, 2025
Showing 1-12 of 4,026

Last Updated: 02/24/2026